04 March 2021
Congratulations to the Royal Cornwall Hospital team, who were top recruiters in February, with 23 patients randomised!
24 February 2021
A warm welcome back to the Southmead Hospital Bristol team, who have restarted recruitment to WHiTE 8 on 19 February. Congratulations on the first two newly recruited participants!
11 February 2021
The WHiTE 8 - COPAL newsletter for February is out! You can read it by clicking this link.
05 February 2021
Congratulations to the Royal Cornwall Hospital team, who were top recruiters for WHiTE 8 in January 2021, with 17 patients randomised!
15 January 2021
The January 2021 edition of newsletter is ready for all site teams to read.
15 January 2021
James Cook Hospital team were top recruiters for the WHiTE8 Copal trial in December 2020.Site team has recruited 21 patients.
08 January 2021
144 patients were recruited in December 2020. Thank you to all site teams for amazing work.s to all of our participating sites!
Fragility hip fractures present a significant global challenge to patients, clinicians and healthcare systems. The global literature confirms an overall mortality risk in the range 10-40% in the first year with much of this attributed to post-operative complications.
Surgical site infection (SSI) is a significant complication with literature for hemiarthroplasty infection stating rates as high as 7.3%. Therefore, the prevention of postoperative complications is likely to be one good way of reducing mortality in this group of patients.
Perioperative antibiotics are one proven means of reducing postoperative infection in patients undergoing hip arthroplasty for any indication. The current standard for cemented hip hemiarthroplasty is the use of parenteral antibiotics in combination with antibiotic loaded cement.
This will be multi centre, multi-surgeon, parallel, two arm, randomised controlled trial. This will be embedded in the World Hip Trauma Evaluation (WHITE) comprehensive cohort.
All adult patients 60 years of age and over presenting at the trial centres, who in the opinion of the treating surgeon require acute surgical treatment with a cemented hip hemiarthroplasty are eligible for inclusion.
The aim of this pragmatic randomised controlled trial is to determine the rate of deep infection in patients treated with either low dose single antibiotic loaded cement or high dose dual antibiotic loaded cement for the treatment of hip fracture with a hemi-arthroplasty.
This study is sponsored by the Northumbria Heathcare NHS Foundation Trust, and is funded by Heraeus Medical. The trial is managed by Oxford Trauma, at the University of Oxford.